Quadriplegia Treatment Market Insights, Research and Growth Factor till 2032

In 2022, the global Quadriplegia Treatment Market is anticipated to be worth $1,468.4 million USD. The market's expansion might be attributed mostly to an increase in the frequency of spinal cord injuries, as well as an increase in the number of car accidents that occur globally each year. Between 2022 and 2032, the global demand for quadriplegia therapy is expected to expand at a CAGR of 4.7%, totalling roughly US$ 2,324.4 Million by 2032.

Key Drivers of Quadriplegia Treatment Market

Quadriplegia is caused by injury to the spinal cord caused by trauma to the base of the neck or the skull. Accidental paralysis, spinal cord tumours, and other spinal cord disorders are some of the most common causes of quadriplegia, also known as tetraplegia. A spinal cord injury can cause limb paralysis, either partial or full. According to the Spinal Cord Injury Statistics 2020 data sheet, approximately 17,810 new cases of spinal cord injuries are expected in the United States per year. Some of the reasons of quadriplegia include stroke, vehicle accidents, falls, violence, sports, medical or surgical causes, and others.

According to WHO estimates, 20-50 million people are injured in road traffic accidents each year, resulting in non-fatal injuries but long-term impairment. The need for quadriplegia therapy is likely to increase over the forecast period due to an increase in traffic accidents. Recent technological improvements and various R&D projects in the field of quadriplegia therapy are two of the key drivers driving demand in the next years. Patients with spinal cord injuries are becoming more aware of the various therapy options available to improve their quality of life.

Key player of Quadriplegia Treatment Market

Major manufacturers of medications needed to treat quadriplegia are

  • Merck & Co.
  • Sanofi Pharmaceuticals
  • Baxter International
  • Zydus Cadila
  • GlaxoSmithKline
  • AstraZeneca
  • Cipla
  • Johnson & Johnson
  • Bristol Myers Squibb Co.
  • Eli Lily & Co.
  • Teva Pharmaceuticals
  • Takeda Pharmaceutical Co Ltd
  • Hoffmann La Roche
  • Sun Pharmaceuticals.

Read More@ https://www.futuremarketinsights.com/reports/quadriplegia-treatment-market

Key Segments

By Treatment Type:

  • Corticosteroids
  • Non- Steroidal Anti-inflammatory Drugs (NSAIDs)
  • Antidepressants
    • Selective serotonin reuptake inhibitors (SSRIs)
    • Serotonin and norepinephrine reuptake inhibitors (SNRIs)
  • Anticonvulsants
  • Narcotic Analgesics
  • Antispasmodics & Muscle Relaxants
  • Antibiotics

By Route of Administration:

  • Oral
  • Intravenous
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Stores

Comments

Post a Comment

Popular posts from this blog

Empowering Diabetics | A Comprehensive Analysis of the Continuous Glucose Monitoring Device Market

Image
According to Future Market Insights' recently released Continuous Glucose Monitoring Device Market Analysis report, global sales of Continuous Glucose Monitoring Device Market in 2022 will be US$ 4.9 Billion. The market is expected to be valued US$ 16.8 billion by 2033, with a CAGR of 11.9% from 2023 to 2033. Market growth is predicted to be driven by an increase in the older population as well as a high prevalence of diabetes. The International Diabetes Federation predicts that the global diabetic population will reach 642 million by 2040. As a result, by 2040, one out of every 10 people would have diabetes, demonstrating the seriousness of the epidemic. Diabetes treatment and management are consequently projected to be a top priority for healthcare administrations and stakeholders around the world. Diabetes cases are predicted to increase, boosting market growth and the potential for continuous glucose monitoring systems, attracting and motivating various industry actors to prod...
Read more

Global Medical face shield Market Insights and Outlook 2022-2032

Image
Medical face shield can become as ubiquitous as masks, as new findings on the airborne spread of Covid-19 influence behavior and guidelines. According to a latest study by Future Market Insights,  Medical Face Shields Market  will grow at over 11% CAGR through 2030. Medical face shields have proven to be an effective first-line defence against airborne diseases such as Zika, SARS, Ebola, flu, and now Covid-19. As a result, increased adoption of medical face shields, and thus increased production, is expected to drive the market during the forecast period. The IDSA (Infectious Diseases Society of America) has included the use of PPE (Personal Protective Equipment) such as face shields and masks in its recommendations. Though masks have been widely used throughout the world, their effectiveness is not widely known. The possibility of cloth masks providing marginal virus protection due to potential moisture retention, poor filtration, and re-use cannot be ruled out. Face ...
Read more

Cognitive Diagnostics Market Projected to Reach Unprecedented Growth by 2033

Image
As per Future Market Insights latest industry analysis, the valuation for the global  Cognitive Diagnostics market sales  is estimated to reach US$ 110.2 Billion in 2023 and is projected to exhibit a CAGR of 8.0% over the forecast period, with an estimated valuation of US$ 238.3 Billion by 2033. Several causes of brain problems or cognitive disorders include closed head injuries, contact with neurotoxins (toxic substances), genetics, infections, strokes, and tumours. Depending on the area of the brain that is impacted, a person may have a certain form of cognitive problem. Communication issues could result from, for instance, a tumour in the speech cisterns of the brain. In another illustration, a brain infection that affects the motor recentres would cause problems with movement. Ageing is also a factor in the development of cognitive problems. Cognitive diagnostics increasingly use digital health technologies like wearables and smartphone apps. These tools can monitor a pati...
Read more